Combination Therapy in IgAN: A Patient Treated with Atrasentan and Targeted-Release Budesonide (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0553; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "The patient was already on max tolerated Lisinopril and Farxiga. The improvement of proteinuria to <0.3 g/day (remission levels per KDIGO) and resolution of hematuria after starting nefecon suggests upstream control of inflammation. This pattern supports the concept that combination therapy may be useful in selected patients when residual disease activity persists and warrants investigation in larger trials."
Clinical • Combination therapy • Fibrosis • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammation • Nephrology • Renal Disease
|
|
Janhvi Rana; Tanvi Deshpande; Yan Chen Wongworawat; Sayna Norouzi
|